Skip to Content
Søk Menu

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

Interview: Real-world data presented at ESMO 2025 indicate that darolutamide may deliver deeper and more durable PSA responses in mHSPC compared with abiraterone. Dr. Alicia Morgans discusses the implications for patient outcomes.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
BlærekreftESMO25 Play the Video 04:57

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

/ Danny Rischin
ESMO25Hudcancer Play the Video 03:46

ESMO 2025: The Future of Oncology Will Be Built by Individuals

/ Jan Andreasen
ESMO25

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
BrystkreftESMO25

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
BrystkreftESMO25
Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatakreft Play the Video 18:34

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatakreft
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostatakreft Play the Video 09:06

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
BlærekreftESMO24NyresykdomProstatakreft
Back to top